By Fineline Cube 
NeuroGen Pharma, a China‑based neurology‑focused biopharmaceutical company co‑founded by CBC Group and Mubadala in 2024, has entered into a strategic cooperation agreement with Harbor No. 8 · GBA Medical Device and Biopharmaceutical Industrial Park. The first‑phase investment of RMB 80 million will establish GMP workshops and automated production lines, scaling capacity for its acquired UCB portfolio and accelerating innovative neurology drug development.
Investment & Partnership Overview
| Item | Detail |
|---|---|
| Company | NeuroGen Pharma (co‑founded by CBC Group & Mubadala, 2024) |
| Partner | Harbor No. 8 · GBA Medical Device and Biopharmaceutical Industrial Park |
| Investment Phase | First phase: RMB 80 million (fixed assets) |
| Use of Funds | High‑standard GMP workshops, multiple automated production lines |
| Strategic Objective | Scale production, upgrade quality standards, accelerate innovative drug translation |
| Core Focus | Neurology therapeutics (licensed‑in global products + independent R&D) |
| Manufacturing Base | Zhuhai plant (UCB‑acquired, international‑standard capabilities) |
Company Foundation & Strategic Moat
Established Through Acquisition:
- 2024 Launch: NeuroGen was created via acquisition of UCB’s mature product portfolio in China, providing immediate revenue base and established commercial infrastructure
- Zhuhai Plant: Leverages UCB’s international‑standard manufacturing facility with existing specialized neurology commercial operations system
- Patient‑Centric Model: Dual strategy of licensing global neurology assets and independent R&D to address China’s neurological disease burden
Market Positioning: Only Mubadala‑backed neurology pure‑play in China, with access to global innovation pipeline through CBC Group’s network.
Market Opportunity: China Neurology Landscape
Disease Burden & Market Size:
- Neurological Disorders: >100 million patients in China across stroke, epilepsy, Parkinson’s, neuropathic pain
- Market Growth: China neurology drug market valued at ¥180 billion (2025), expanding at 14% CAGR
- Unmet Need: 60‑70% of neurology patients lack access to innovative therapies; reliance on generic drugs
Growth Drivers:
- Aging population increasing stroke and neurodegenerative disease prevalence
- Rising diagnosis rates for epilepsy and neuropathic pain
- Government push for domestic production of critical CNS drugs
Strategic Rationale for GBA Park Investment
Why Harbor No. 8 · GBA Park?
- Ecosystem Synergy: GBA Park houses 50+ biopharma and medtech companies, creating collaboration opportunities in cardiopulmonary and neuro‑interventional technologies
- Regulatory Fast‑Track: Park offers priority NMPA consultation and innovative device designation support
- Talent Pool: Access to Shenzhen‑Hong Kong‑Macau corridor’s 2,000+ experienced biotech engineers
- Infrastructure: Turnkey GMP‑ready facilities reduce time‑to‑production by 12‑18 months
Production Scaling: The RMB 80 million investment will triple NeuroGen’s manufacturing capacity to support 5‑8 product launches by 2028.
Financial Projections & Use of Proceeds
Investment Breakdown (RMB 80 million):
| Category | Amount (RMB million) | % of Investment | Timeline |
|---|---|---|---|
| GMP Workshop Construction | 45 | 56.3% | Q1‑Q4 2026 |
| Automated Production Lines | 25 | 31.3% | Q2 2026‑Q2 2027 |
| Quality System Upgrades | 6 | 7.5% | Ongoing |
| R&D Equipment & Tech Transfer | 4 | 5.0% | Q3 2026 |
Revenue Impact:
- 2026E: ¥800‑1,000 million (UCB portfolio ramp)
- 2028E: ¥2.5‑3.0 billion (with new GMP capacity)
- 2030E: ¥5.0 billion (with 5+ innovative products)
Gross Margin: Expected to improve from 65% to 78% via automation and scale.
Pipeline Expansion & Innovation Strategy
Licensed‑In Strategy: NeuroGen is in discussions to acquire 2‑3 additional neurology assets from European biotechs in 2026, leveraging Mubadala’s global network.
Independent R&D: Zhuhai R&D center will focus on novel targets for neuropathic pain and Parkinson’s disease, with first IND filing planned for H2 2027.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding NeuroGen Pharma’s investment timeline, capacity expansion, revenue projections, and pipeline development. Actual results may differ materially due to construction delays, regulatory approvals, competitive dynamics, and integration challenges with the acquired UCB portfolio.-Fineline Info & Tech